MoonLake Immunotherapeutics (MLTX) Treasury Shares (2020 - 2025)

MoonLake Immunotherapeutics' Treasury Shares history runs 1 years deep, the most recent figure standing at $6202.0 for Q4 2021.

• On a quarterly basis, Treasury Shares fell 88.91% year-over-year to $246302.0 in Q1 2025; TTM through Mar 2025 was $246302.0, a 88.91% decrease from a year earlier, with the FY2024 full-year figure at $319769.0, down 49.28% from the prior year.
• Treasury Shares slipped to $246302.0 in Q1 2025 per MLTX's latest filing, from $319769.0 in the prior quarter.
• Across five years, Treasury Shares topped out at $2.8 million in Q2 2022 and bottomed at $246302.0 in Q1 2025.
• The 5-year median for Treasury Shares is $2.2 million (2024), against an average of $1.7 million.
• Across the five-year window, Treasury Shares jumped 192.35% in 2023 and tumbled 88.91% in 2025, its largest moves.
• Year by year, Treasury Shares stood at $1.9 million in 2021, then rose by 3.05% to $1.9 million in 2022, then slumped by 67.54% to $630490.0 in 2023, then sank by 49.28% to $319769.0 in 2024, then decreased by 22.98% to $246302.0 in 2025.
• Per Business Quant, the three latest MLTX Treasury Shares figures stand at $246302.0 (Q1 2025), $319769.0 (Q4 2024), and $2.2 million (Q3 2024).